A sejten kívüli szabad DNS felszabadulásának és                     degradációjának <i>in vivo</i> elemzése

Barták, Barbara Kinga; Nagy, Zsófia Brigitta; Spisák, Sándor; Tulassay, Zsolt; Dank, Magdolna; Igaz, Péter; Molnár, Béla

doi:10.1556/650.2018.30929

Cited by 4 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yapılan çalışmalarda, metile olmayan hdDNA'nın 6 saatte ortadan kaybolduğu, metillenmiş hdDNA'nın 24 saatten daha uzun sürede bile tespit edilebildiği, tümörlü hayvanlarda ise hem metillenmiş hem de metillenmemiş hdDNA'nın 24 saatten daha uzun sürede tespit edilebildiği gösterilmiştir (30). Vücutta uzun süre kalabilen bu serbestçe dolaşan DNA parçalarının farklı hücreleri transfekte edip edemeyeceği ve metastazı kolaylaştırıp kolaylaştıramayacağı araştırılmaya başlanmıştır.…”

Section: Genometastaz Ve Hddnaunclassified

Cell Free DNA and Genometastasis

Koçana¹,

Toprak²,

Yaşa³

et al. 2019

Experimed

View full text Add to dashboard Cite

Cell free DNAs (cfDNA) are short DNA fragments which are present in all biological fluids and cell culture medium. They were first detected in blood plasma by Mandel and Metais in 1948. cfDNAs are mostly endogenous-derived fragments that are determined in lipid/protein rich complexes or particles with membranes. In healthy individuals, there are small amounts of mono-nucleosome forms of cfDNA in the peripheral circulation. cfDNA can bind to proteins and phospholipids on cell surfaces. This mechanism may related to absorbance and release of cfDNA. Different enzymes such as deoxyribonuclease (DNase) may facilitate the unbounding and recirculation of membrane bound cfDNAs.

show abstract

Section: Genometastaz Ve Hddnaunclassified

Cell Free DNA and Genometastasis

Koçana¹,

Toprak²,

Yaşa³

et al. 2019

Experimed

View full text Add to dashboard Cite

show abstract

Extracellular Nucleic Acids in the Diagnosis and Progression of Colorectal Cancer

Styk

Buglyó

Pös

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the 3rd most common malignant neoplasm worldwide, with more than two million new cases diagnosed yearly. Despite increasing efforts in screening, many cases are still diagnosed at a late stage, when mortality is high. This paper briefly reviews known genetic causes of CRC (distinguishing between sporadic and familial forms) and discusses potential and confirmed nucleic acid biomarkers obtainable from liquid biopsies, classified by their molecular features, focusing on clinical relevance. We comment on advantageous aspects such as better patient compliance due to blood sampling being minimally invasive, the possibility to monitor mutation characteristics of sporadic and hereditary CRC in a disease showing genetic heterogeneity, and using up- or down-regulated circulating RNA markers to reveal metastasis or disease recurrence. Current difficulties and thoughts on some possible future directions are also discussed. We explore current evidence in the field pointing towards the introduction of personalized CRC management.

show abstract

Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients

et al. 2021

View full text Add to dashboard Cite

Breast cancer is the most common malignancy in women, with alarming mortalities. Neoadjuvant treatments employ chemotherapy to shrink tumours to a well-defined size for a better surgical outcome. The current means of assessing effectiveness of chemotherapy management are imprecise. We previously showed that breast cancer patients have higher serum circulating cell-free DNA concentrations. cfDNA is degraded cellular DNA fragments released into the bloodstream. We further report on the utility of cfDNA in assessing the response to chemotherapy and its potential as a monitoring biomarker. A total of 32 newly diagnosed and treatment-naive female breast cancer patients and 32 healthy females as controls were included. Anthropometric, demographic and clinicopathological information of participants were recorded. Each participant donated 5 mL of venous blood from which sera were separated. Blood sampling was carried out before the commencement of chemotherapy (timepoint 1) and after the third cycle of chemotherapy (timepoint 2). qPCR was performed on the sera to quantify ALU 115 and 247 levels, and DNA integrity (ALU247/ALU115) was determined. ALU 115 and 247 levels were elevated in cancer patients but were significantly decreased after the third cycle of chemotherapy (T2) compared to T1. DNA integrity increased after the third cycle. Serum cfDNA may provide a relatively inexpensive and minimally invasive procedure to evaluate the response to chemotherapy in breast cancer.

show abstract

A sejten kívüli szabad DNS felszabadulásának és degradációjának in vivo elemzése

Cited by 4 publications

References 33 publications

Cell Free DNA and Genometastasis

Cell Free DNA and Genometastasis

Extracellular Nucleic Acids in the Diagnosis and Progression of Colorectal Cancer

Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients

Contact Info

Product

Resources

About